New Product VAN (Vancomycin Hydrochloride Capsules) Launch Kick-off Meeting successfully held

On October 15–16, Mayoly China New Product VAN Launch Kick-off Meeting was grandly held. It was a gathering that built consensus and ignited passion, where all colleagues officially sounded the charge to bring the new product to the market — breaking through challenges with expertise and setting sail with confidence.

Leveraging the strong brand and academic influence hospital team has built through years of deep cultivation in the gastroenterology field, this new product launch will center on Gastroenterology IBD (Inflammatory Bowel Disease) while engaging multidisciplinary collaboration with ICU, Pediatrics, and other specialties. Through efficient product portfolios and resource integration, we aim to achieve rapid breakthroughs and provide patients with diversified solutions covering primary screening and diagnosis, treatment and dynamic efficacy monitoring, and relapse prediction — truly enabling full-disease-course management.

Three core advantages of the product:

  1. In the China’s National Reimbursement Drug List (NRDL), and the unique vancomycin capsule formulation in China.
  2. First Hard Capsule in China — Patented technology, intestinal-targeted action, highly effective local bactericidal effect, and high safety without systemic absorption.
  3. Priority Review Drug for Pediatrics — Fills the gap in China for oral treatment of Clostridioides difficile infection in both adults and children under 18.

Putting patients at the center and translating our pursuit of innovation into accessible clinical solutions is Mayoly’s long-term commitment to taking root in China and serving patients.

In the face of challenges, Mayoly responds with expertise; as we embrace the new journey, we answer with confidence. The charge has been sounded — let us join hands and move forward at full speed to create outstanding results together!

No comments yet, be the first to comment.

Залишити відповідь